MB, Levis & Associates’s Gilead Sciences GILD Stock Holding History

MB, Levis & Associates’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-200	Closed	-$22.2K	–	269
2025 Q2	$22.2K	Hold	200	–	–	0.01%	162
2025 Q1	$22.4K	Hold	200	–	–	0.01%	158
2024 Q4	$18.5K	Hold	200	–	–	0.01%	162
2024 Q3	$16.8K	Hold	200	–	–	0.01%	168
2024 Q2	$13.7K	Hold	200	–	–	0.01%	176
2024 Q1	$14.6K	Hold	200	–	–	0.01%	171
2023 Q4	$16.2K	Hold	200	–	–	0.01%	163
2023 Q3	$15K	Hold	200	–	–	0.01%	173
2023 Q2	$15.4K	Hold	200	–	–	0.01%	172
2023 Q1	$16.6K	Hold	200	–	–	0.01%	169
2022 Q4	$17.2K	Buy	+200	New	+$15.8K	0.01%	158

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MB, Levis & Associates's GILD Position: Q3 2025 in Review

MB, Levis & Associates sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 200 shares — an estimated $22.2K sold.

MB, Levis & Associates first reported a position in GILD in Q4 2022 and held it in 11 quarters. The position peaked at $22.4K in Q1 2025. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

MB, Levis & Associates reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
MB, Levis & Associates sold 200 Gilead Sciences shares in Q3 2025, an estimated $22.2K.
MB, Levis & Associates first reported a position in Gilead Sciences in Q4 2022 and held it in 11 quarters.
MB, Levis & Associates's Gilead Sciences position peaked at $22.4K in Q1 2025.
2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on MB, Levis & Associates's 13F filing for Q3 2025, filed 15 Oct 2025.